Compare BIO-TECHNE Corp (TECH) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Western Alliance Bancorporation — how do they compare? BIO-TECHNE Corp trades at $71.63 (market cap $11.16B), while Western Alliance Bancorporation trades at $79.8 (market cap $8.84B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and Western Alliance Bancorporation pays the higher dividend (2.07%). Which is the better fit depends on your goals.
| TECH | WAL | |
|---|---|---|
Market Cap | $11.16B | $8.84B |
Sector | Health | Financials |
52-Week High | $72.12 | $96.08 |
52-Week Low | $43.31 | $66.70 |
Enterprise Value | $11.24B | — |
Dividend Yield | 0.45% | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Western Alliance Bancorporation (WAL) trades at $80.97, down 1.62% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company has consistently beaten earnings estimates in recent quarters, with a Q2 2026 EPS estimate of $2.33. Strong profitability is evident with a net income margin of 25.63% and ROE of 13.47%, while valuation ratios like a P/E of 9.58 suggest potential undervaluation. Recent news highlights operational achievements, including being named Arizona's #1 bank by Forbes in June 2026.
The outlook for WAL is positive, supported by analyst consensus with 79% buy ratings and a $90.67 price target, implying ~12% upside. Investment opportunities include earnings growth and sector leadership, but risks involve negative operating cash flow in 2025 and high interest expenses of $1.83B that could pressure margins if rates rise.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
